Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pluri Inc PLUR

Healthcare Biotechnology
Pluri Inc., formerly known as Pluristem Therapeutics Inc., is an Israel-headquartered company engaged in the research and provision of cell-based products directed for a range of industries. The Company is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical... see more

Recent & Breaking News (NDAQ:PLUR)

Pluristem Reports Topline Results from its Phase II Studies of Acute Respiratory Distress Syndrome Associated with COVID-19

GlobeNewswire December 27, 2021

Pluristem Completes Enrollment of Its Multinational Phase III Study of Muscle Regeneration Following Hip Fracture Surgery

GlobeNewswire November 15, 2021

Pluristem Receives Approval for Grant from the Israel Innovation Authority to Develop its Next-Generation CRISPR PLX Platform

GlobeNewswire November 10, 2021

Pluristem CEO Issues Shareholder Update

GlobeNewswire September 22, 2021

Pluristem Appoints Prof. Varda Shalev MD and Mr. Doron Birger to Join its Board of Directors

GlobeNewswire July 19, 2021

Pluristem Brings ARDS Associated with COVID-19 Phase II Studies to Clinical Readout

GlobeNewswire July 8, 2021

Pluristem to Receive Euro20M Non-Dilutive Funding from the European Investment Bank

GlobeNewswire May 25, 2021

Pluristem reports positive topline Phase I results in innovative hematology program, which is first to study PLX-R18 in humans

GlobeNewswire April 29, 2021

Pluristem Therapeutics Inc. Announces $30 Million Registered Direct Offering

GlobeNewswire February 2, 2021

Pluristem Announces Uplisting to the Nasdaq Global Market®

GlobeNewswire January 27, 2021

Pluristem Announces Appointments of Two Directors to Board

GlobeNewswire January 6, 2021

Pluristem Enters Collaboration With Pharmaceutical Company Innovare R&D to Expand Pluristem's ARDS Associated With COVID-19 Program to Mexico

GlobeNewswire December 29, 2020

Pluristem Announces DMC Recommendation Following Interim Analysis of its Phase III CLI Study

GlobeNewswire December 9, 2020

Pluristem to Present Initial Results from Its Phase I HCT Study with PLX-R18 Demonstrating Safety and Efficacy at the ASH Annual Meeting

GlobeNewswire November 18, 2020

World Experts in Infectious Diseases & Critical Care Form Pluristem's COVID-19 Steering Committee

GlobeNewswire October 20, 2020

Pluristem Announces Clearance to Move Forward with Enrollment for Cohort II in an Investigator-Led Phase I/II Chronic Graft vs Host Disease Study

GlobeNewswire October 13, 2020

Pluristem Expands its Phase II COVID-19 European Clinical Trial to Israel

GlobeNewswire October 7, 2020

Abu Dhabi Stem Cells Center and Pluristem Unveil Joint Projects at Malta Conferences Foundation Online Event

GlobeNewswire October 1, 2020

Pluristem CEO Issues Shareholder Update

GlobeNewswire September 15, 2020

Pluristem Launches FDA-Cleared COVID-19 Expanded Access Program, Enabling Patient Treatment Outside of Clinical Trial

GlobeNewswire August 27, 2020